Omeprazolo Aurobindo Pharma Italia (Omeprazole)

Omeprazole, the active ingredient in Omeprazolo Aurobindo Pharma Italia, is a proton pump inhibitor presented as a 20 mg tablet for oral use. It reduces gastric acid secretion and is employed in the treatment of acid‑related disorders such as gastro‑oesophageal reflux disease, peptic ulcer disease and Zollinger‑Ellison syndrome in adults.

GNH USA supplies Omeprazolo Aurobindo Pharma Italia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related conditions: - Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid production. - Helicobacter pylori eradication regimens (as adjunct): enhances eradication rates when combined with antibiotics. - NSAID‑associated ulcer prophylaxis: lowers the risk of ulcer development in chronic NSAID users.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: usually transient. - Nausea or abdominal discomfort: occasional. - Flatulence: mild bloating. - Constipation: infrequent. - Dry mouth: occasional.

Serious or Rare Side Effects: - Acute interstitial nephritis: signs of renal impairment. - Severe allergic reactions: rash, angioedema, anaphylaxis. - Clostridioides difficile infection: persistent diarrhoea. - Osteoporotic fractures: long‑term high‑dose use. - Hypomagnesemia: muscle cramps, arrhythmia. - Vitamin B12 deficiency: neuropathy with prolonged therapy.

When prescribing Omeprazole, clinicians should consider several safety aspects: - Assess renal and hepatic function: dose adjustment may be needed in severe impairment. - Review concomitant medications: potential for drug‑drug interactions. - Monitor long‑term users: watch for bone density loss and electrolyte disturbances. - Use caution in pregnancy: weigh maternal benefit against potential fetal risk. - Evaluate for Helicobacter pylori infection before initiating therapy. - Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir and other protease inhibitors: markedly decreased antiviral exposure. - Methotrexate (high dose): increased serum concentrations, risk of toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR, require more frequent monitoring. - Digoxin: modest increase in serum levels. - Diazepam: enhanced sedation, monitor CNS effects. - Iron salts: reduced absorption, separate dosing by at least 2 hours.